Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10275396 | 0.84 | PDE5A (0.48) | PDE5ATSHRHTTKDM4ECREBBP | |
| SCHEMBL10313633 | 0.78 | XDH (0.42) | PDE5AMEN1KMT2A | |
| SCHEMBL10313642 | 0.77 | CYP17A1 (0.38) | TSHRHTTKDM4EEGFRALDH1A1 | |
| SCHEMBL10313638 | 0.76 | TSHR (0.54) | PDE5ATSHRHTTALDH1A1HPGD | |
| SCHEMBL6103701 | 0.70 | ALDH1A1 (0.78) | PDE5ATSHRHTTKDM4ECREBBP | |
| SCHEMBL10313637 | 0.67 | CSNK2A2 (0.47) | PDE5ATSHRKDM4EALDH1A1HPGD | |
| SCHEMBL25341255 | 0.65 | LMNA (0.58) | TSHRHTTKDM4ECREBBPALDH1A1 | |
| SCHEMBL1753160 | 0.65 | TP53 (0.62) | TSHRHTTKDM4EALDH1A1HPGD | |
| SCHEMBL25343005 | 0.63 | PDE9A (0.44) | PDE5ATSHRHTTKDM4ECREBBP | |
| SCHEMBL25343768 | 0.63 | PDE9A (0.46) | PDE5ATSHRHTTKDM4ECREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | XU LIFENG (US) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178915-A1 | PYRIMIDINE DERIVATIVES AND ANALOGS, PREPARATION METHOD AND USE THEREOF | TYMP, TYMS, ADORA3 | PDE5A 2719/4885TSHR 1051/4885HTT 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.